title: Combination effect of anti-Fas antibody and chemotherapeutic drugs in ovarian cancer cells in vitro.
abstract: To clarify the significance of the Fas antigen (Ag) in gynecologic tumors, its expression in gynecologic cancer cell lines was examined. The Fas Ag was expressed in 6 of 15 cell lines. Five of 8 ovarian cancer cell lines but none of 4 choriocarcinoma cell lines expressed the Fas Ag. In drug-resistant cell lines derived from one of the Fas-positive cells, its expression was not lost after development of resistance to cisplatin, SN-38 or etoposide, but its expression was absent in the cell line resistant to Adriamycin. The effect of the anti-Fas antibody (Ab) was then studied. Apoptosis was induced in 7 of 9 Fas-positive cell lines, whereas the remaining two cell lines were unaffected. Furthermore, the combination effect of the anti-Fas Ab and drugs was examined in an ovarian cancer cell line and its drug-resistant variants, and a synergistic effect was observed. These results suggest important roles of the Fas Ag in ovarian cancer and the potential for overcoming drug resistance by a combination of the anti-Fas Ab and various drugs.
authors.affiliation: Department of Obstetrics and Gynecology, Nagoya University School of Medicine, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Wakahara
authors.forename: A
authors.initials: A
authors.lastname: Nawa
authors.forename: T
authors.initials: T
authors.lastname: Okamoto
authors.forename: A
authors.initials: A
authors.lastname: Hayakawa
authors.forename: F
authors.initials: F
authors.lastname: Kikkawa
authors.forename: N
authors.initials: N
authors.lastname: Suganama
authors.forename: F
authors.initials: F
authors.lastname: Wakahara
authors.forename: Y
authors.initials: Y
authors.lastname: Tomoda
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D005833:Genital Neoplasms, Female / Q000628:therapy; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000628:therapy*; D014407:Tumor Cells, Cultured; D019014:fas Receptor / Q000276:immunology*
chemical_list: D019014:fas Receptor